Study on the mechanism of Juanxiao decoction in improving bronchial asthma
- VernacularTitle:蠲哮汤改善支气管哮喘的机制研究
- Author:
Bangqing CAO
1
;
Qiangqiang YU
2
;
Meinian LIU
1
;
Zhixi WU
1
;
Lizhen ZENG
1
;
Mengyao TONG
1
;
Yunhua DENG
1
;
Hanrong XUE
1
Author Information
1. Dept. of Pulmonary Diseases，the Second Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine，Nanchang 330012，China
2. Dept. of Pulmonary Diseases，the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine，Nanchang 330006，China
- Publication Type:Journal Article
- Keywords:
Juanxiao decoction;
bronchial asthma;
NLRP3 inflammasome signaling pathway
- From:
China Pharmacy
2026;37(2):155-160
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the potential mechanism by which Juanxiao decoction improves bronchial asthma （hereinafter referred to as “asthma”） based on the nucleotide-binding domain leucine-rich repeat and pyrin domain-containing receptor 3 （NLRP3） inflammasome signaling pathway. METHODS Female SD rats were randomly assigned to normal group， model group and Juanxiao decoction low-， medium- and high-dose groups （0.36， 0.72 and 1.44 g/kg， calculated based on crude drug weight）， as well as positive control group （Dexamethasone acetate tablets， 0.2 mg/kg）， with 10 rats in each group. Except for the normal group， asthma models were established in the remaining groups via intraperitoneal injection of ovalbumin combined with aluminum hydroxide， followed by nebulized inhalation of ovalbumin. On day 14 of the experiment， rats in each group received intragastric administration of the corresponding solution or normal saline， once a day， for 7 consecutive days. Following the final administration， the following parameters were measured in each group： lung function indexes （forced vital capacity， forced expiratory volume in 0.3 second， peak expiratory flow）， serum levels of inflammatory markers （interleukin-1β， interleukin- 18）， and the percentages of inflammatory cells （lymphocytes， eosinophils， neutrophils） in bronchoalveolar lavage fluid. Histopathological changes in lung tissue were observed， and the protein and mRNA expressions of nuclear factor-kappa B （NF- κB）， NLRP3 and caspase-1 in lung tissue were detected. RESULTS Compared with the normal group， pathological changes such as alveolar wall thickening and inflammatory cell infiltration were observed in rats in the model group. All pulmonary function indicators were significantly reduced in rats in the model group and the administration groups. The levels of inflammatory markers， the percentages of inflammatory cells， and the protein and mRNA expressions of NF-κB， NLRP3 and caspase-1 were significantly elevated or up-regulated （P＜0.05）. Compared with the model group， pathological changes in rats in each dosage group of Juanxiao decoction were significantly alleviated， and all quantitative indicators showed dose-dependent improvements （P＜0.05）. CONCLUSIONS Juanxiao decoction can reduce airway inflammatory responses in asthmatic rats， alleviate lung function impairment， and improve pathological changes such as inflammatory cell infiltration. Those effects may be related to the inhibition of the NLRP3 inflammasome signaling pathway.
